43 reports of this reaction
2.5% of all NAFCILLIN SODIUM reports
#6 most reported adverse reaction
TUBULOINTERSTITIAL NEPHRITIS is the #6 most commonly reported adverse reaction for NAFCILLIN SODIUM, manufactured by Athenex Pharmaceutical Division, LLC.. There are 43 FDA adverse event reports linking NAFCILLIN SODIUM to TUBULOINTERSTITIAL NEPHRITIS. This represents approximately 2.5% of all 1,697 adverse event reports for this drug.
Patients taking NAFCILLIN SODIUM who experience tubulointerstitial nephritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TUBULOINTERSTITIAL NEPHRITIS is a less commonly reported adverse event for NAFCILLIN SODIUM, but still significant enough to appear in the safety profile.
In addition to tubulointerstitial nephritis, the following adverse reactions have been reported for NAFCILLIN SODIUM:
The following drugs have also been linked to tubulointerstitial nephritis in FDA adverse event reports:
TUBULOINTERSTITIAL NEPHRITIS has been reported as an adverse event in 43 FDA reports for NAFCILLIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
TUBULOINTERSTITIAL NEPHRITIS accounts for approximately 2.5% of all adverse event reports for NAFCILLIN SODIUM, making it a notable side effect.
If you experience tubulointerstitial nephritis while taking NAFCILLIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.